Agenus (NasdaqCM:AGEN) FY Conference September 09, 2025 10:00 AM ET Speaker2Good morning, everyone. Thank you for joining us at the HC Wainwright 27th Annual Global Investment Conference. My name is Emily Bodnar. I'm an Equity Research Analyst at HC Wainwright. Pleased to be doing a fireside chat with Agenus. We have Richard Goldberg, Chief Development Officer, and Robin Taylor, Chief Commercial Officer of the company here. Maybe to start, for those a bit newer to the story, your lead asset, Botensilimab, i ...

Core Insights - The conference call will focus on the growing colorectal cancer crisis and emerging data from the BOT/BAL immunotherapy program [5] - The discussion will include perspectives from leading clinicians and address systemic regulatory challenges that delay access to life-extending treatments [5] Company Participants - Key executives from Agenus participating in the call include Garo H. Armen (Founder, Executive Chairman & CEO), Jennifer S. Buell (Director and President & CEO of MiNK Therapeutics), Richard M. Goldberg (Chief Development Officer), Stefanie Perna-Nacar (Chief Communications & Government Relations Officer), and Steven J. O'Day (Chief Medical Officer) [1][3] External Participants - The call will feature external thought leaders such as Dr. Nicholas DeVito (Assistant Professor of Medical Oncology, Duke University) and Dr. Chris O'Callaghan (Senior Investigator, Canadian Cancer Trials Group) [4]

Agenus (AGEN) Update / Briefing August 27, 2025 04:00 PM ET Company ParticipantsStefanie Perna Nacar - Chief Communications & Government Relations OfficerGaro Armen - Founder, Executive Chairman & CEORichard Goldberg - Chief Development OfficerNicholas DeVito - Assistant ProfessorChristopher O'Callaghan - Senior InvestigatorJennifer Buell - CEO - MiNK Therapeutics & Chair of Executive Committee - AgenusSteven O’Day - Chief Medical OfficerStefanie Perna NacarGood afternoon. My name is Stephanie Nakar and I'm ...

Core Viewpoint - Agenus reported a quarterly loss of $1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.78, but an improvement from a loss of $2.52 per share a year ago [1] Financial Performance - The company posted revenues of $25.7 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.68% and showing an increase from $23.51 million in the same quarter last year [2] - Over the last four quarters, Agenus has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Agenus shares have increased approximately 75.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimate for the coming quarter at -$0.20 on revenues of $24.97 million, and for the current fiscal year at $1.56 on revenues of $246.08 million [7] - The estimate revisions trend for Agenus was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Agenus belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Del ...

[FORM 8-K CURRENT REPORT](index=1&type=section&id=FORM%208-K%20CURRENT%20REPORT) This current report provides essential administrative and financial disclosures, including operational results and exhibit details, as mandated by SEC regulations [Filing Information](index=1&type=section&id=Filing%20Information) This section details the registrant's administrative information, including company name, jurisdiction, and stock exchange listing - Registrant is **Agenus Inc.**, incorporated in Delaware[2](index=2&type=chunk) Registered Securities Information | Title of each class | Symbol(s) | Name of each exchange on which registered | | :------------------ | :-------- | :---------------------------------------- | | Common Stock, $0.01 par value per share | AGEN | The Nasdaq Global Market | - The registrant is not an emerging growth company[5](index=5&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=3&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This section reports Agenus Inc.'s financial results for the quarter ended June 30, 2025, furnished via a press release - Agenus Inc. announced financial results for the quarter ended **June 30, 2025**, on **August 11, 2025**[6](index=6&type=chunk) - A press release, **Exhibit 99.1**, detailing financial results is furnished with this Form 8-K[6](index=6&type=chunk) - Information in Item 2.02 and Exhibit 99.1 is furnished, not filed, exempting it from Section 18 liabilities of the Securities Exchange Act of 1934[7](index=7&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section identifies the exhibits furnished with the Form 8-K, specifically Exhibit 99.1, the Press Release - **Exhibit 99.1** is the Press Release dated **August 11, 2025**[8](index=8&type=chunk) [Signatures](index=4&type=section&id=SIGNATURES) This section confirms the report's official signing by Christine M. Klaskin, VP, Finance, on August 11, 2025 - The report was signed on **August 11, 2025**[11](index=11&type=chunk) - Signed by **Christine M. Klaskin**, VP, Finance[11](index=11&type=chunk)

Key Takeaways Top executives and analysts focus on consistent earnings growth, which reflects a company's profitability. However, earnings acceleration has an even greater impact on driving up stock prices. Studies show that successful stocks experience a speed-up in earnings before their stock prices increase. To that end, QuantumScape Corporation (QS) , Civeo Corporation (CVEO) and Agenus Inc. (AGEN) are exhibiting strong earnings acceleration this month. What is Earnings Acceleration? EPS % Growth (Q0)/( ...

Company Overview - Agenus (AGEN) shares increased by 19.3% to $7.06 in the last trading session, with a notable trading volume, and have gained 22.8% over the past four weeks [1][2] Clinical Data - The company announced positive clinical results for its combination therapy of botensilimab and balstilimab (BOT/BAL) in patients with microsatellite-stable metastatic colorectal cancer, showing a two-year survival rate of 42% in an expanded cohort of 123 patients, with a median overall survival of 21 months [2] Financial Expectations - Agenus is projected to report a quarterly loss of $0.78 per share, reflecting a year-over-year increase of 69.1%, with expected revenues of $25.03 million, up 6.5% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Agenus is part of the Zacks Medical - Biomedical and Genetics industry, where Illumina (ILMN) closed 0.8% lower at $99.25, having returned 13.5% in the past month [5] - Illumina's consensus EPS estimate for its upcoming report is $1.02, representing a year-over-year change of 183.3%, and it currently holds a Zacks Rank of 3 (Hold) [6]

Core Insights - The focus on steady earnings growth is essential for assessing a company's profitability, but rapid earnings growth can significantly drive stock prices higher [1] - Research indicates that stocks with accelerating earnings often see their prices increase subsequently [1] Earnings Acceleration - Earnings acceleration refers to the incremental growth in a company's earnings per share (EPS), characterized by an increase in quarter-over-quarter earnings growth rates [3] - This metric helps identify stocks that have not yet attracted investor attention, potentially leading to a price rally once recognized [4] Screening Parameters - The screening process involves identifying stocks where the last two quarter-over-quarter EPS growth rates exceed previous periods' growth rates, with projected EPS growth rates for the upcoming quarter expected to surpass prior periods [6][7][8] - Additional criteria include a current price of at least $5 and an average 20-day trading volume of 50,000 or more to ensure adequate liquidity [8] Identified Stocks - The screening narrowed down to three stocks: Yext, Agenus, and NCR Voyix, all showing strong earnings acceleration [9] - NCR Voyix leads with an expected EPS growth rate of 152.7%, followed by Agenus at 114.7% and Yext at 37.1% for the current year [9] Company Profiles - **Yext**: Provides a platform for consumer inquiries globally, with an expected earnings growth rate of 37.1% [10] - **Agenus**: A biotechnology firm focused on developing immune therapies for cancer and infections, with an expected earnings growth rate of 114.7% [11] - **NCR Voyix**: Offers digital commerce solutions for retail and dining, with an expected earnings growth rate of 152.7% [12]

Group 1 - CVS Health is part of the Medical group, which consists of 996 companies and is currently ranked 7 in the Zacks Sector Rank [2] - CVS Health has a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for CVS' full-year earnings has increased by 4% in the past quarter, reflecting improved analyst sentiment [3] Group 2 - CVS Health has gained approximately 51.8% year-to-date, significantly outperforming the average loss of 3.9% in the Medical sector [4] - Another outperforming stock in the Medical sector is Agenus, which has returned 79.2% year-to-date [4] - CVS Health belongs to the Medical Services industry, which has gained an average of 0.3% this year, indicating better performance compared to the industry average [5] Group 3 - Investors interested in the Medical sector should monitor CVS Health and Agenus for their strong performance [6]